GlassScriptPhysician profile
Katie J Dye
NPI 1760700363
$1,599.61
in general payments reported to CMS, 2019-2025
22 companies · $460 in 2025
The $460 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.08 · 2022: $153 · 2023: $705 · 2024: $270 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,433.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $659.02 | 2023-2025 | |
| Glaxosmithkline, LLC. | $142.62 | 2021-2024 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $140.02 | 2022-2025 | Jardiance, Emgality, Zepbound |
| Novo Nordisk INC | $76.32 | 2022-2025 | Rybelsus, Ozempic, Saxenda |
| Exact Sciences Corporation | $68.62 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $61.72 | 2023-2025 | |
| Axsome Therapeutics, INC. | $46.71 | 2023-2024 | Auvelity |
| Alkermes, INC. | $40.12 | 2023 | Aristada, Lybalvi |
| Astellas Pharma US INC | $37.12 | 2023-2025 | Veozah |
| Abbott Laboratories | $36.40 | 2025 | |
| Amgen INC. | $32.29 | 2024-2025 | Otezla, Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $29.95 | 2023 | Camzyos |
| Indivior INC. | $28.56 | 2024 | Sublocade |
| Bayer Healthcare Pharmaceuticals INC. | $27.84 | 2023 | |
| Daiichi Sankyo INC. | $26.09 | 2025 | Enhertu |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $24.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.41 | 2025 | Jardiance |
| Lundbeck LLC | $22.93 | 2022 | |
| Boston Scientific Corporation | $21.50 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $20.79 | 2023 | Farxiga |
| Alnylam Pharmaceuticals INC. | $18.45 | 2023 | Givlaari |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.13 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Dye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.